Veracyte, Inc. (VCYT)
POSITIVEファンダメンタル
74
株価
$43.65
時価総額
$3.32B
パート1 · 企業の価値
概要
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
貸借対照表と流動性
売上高
$562M
直近12か月（2026/6/30まで）
純利益
$114M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$127M
自己資本合計
$1.31B
負債合計
$96M
流動比率
9.16
利払い倍率
-
負債/EBITDA
0.51
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$43.39
現在株価
$43.65
安全マージン
-0.6%
適正価値レンジ
$28.21 - $58.58
推定方法
バリュエーション指標
P/E レシオ
29.62
ROE
5.1%
P/B レシオ
2.40
P/FCF
20.08
粗利益率
71.7%
ROIC
5.9%
収益性レーダー
Value Creation (Economic Moat)
ROIC
5.9%
WACC
15.2%
ROIC − WACC
-9.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
ファンダメンタル分析基準
合格（20）
- EPS shows upward trend
- Price CAGR 18.52%
- ROIC 5.9%
- Gross Margin 71.7%
- P/FCF 20.08
- P/B Ratio 2.40
- Debt/Equity ratio
- Operating Margin 18.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 8.6%
- Revenue Growth 5Y 34.5%
- Analyst Consensus 84% Buy
- Earnings Surprise avg 93.2%
- Earnings Quality (OCF/NI) 1.56
- Net Margin Trend 20.4% vs 5.5%
- Piotroski F-Score 8/9
不合格（4）
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Share Dilution 3.9%
データなし（3）
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-スコア
財務健全性が高い
利益の質
高品質：利益はキャッシュに裏付けられている
株式希薄化
新株を発行しており、所有権を希薄化している
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Mr. Marc A. Stapley | CEO & Director | 55 |
| Ms. Rebecca Chambers | Executive VP & CFO | 47 |
| Dr. Phillip G. Febbo M.D. | Chief Scientific & Medical Officer | 59 |
| Ms. Annie McGuire | Executive VP, General Counsel & Head of Market Access | 44 |
| Dr. John Leite Ph.D. | Global Chief Commercial Officer | 53 |
| Dr. Keith Gligorich Ph.D. | Senior Vice President of Global Operations | - |
| Mr. Jonathan Wygant | VP & Chief Accounting Officer | 54 |
| Dr. Kevin Richard Haas Ph.D. | Chief Development and Technology Officer | 40 |
| Mr. Steven French | Senior VP & Chief Information Officer | - |
| Ms. Kelly Gura | Director of Investor Relations | - |
監査リスク
2
取締役会リスク
2
報酬リスク
5
株主権利リスク
4
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
Latest News
Recent headlines for VCYT, sourced from Markets Gazette.
- 2/25/2026NEUTRALVeracyte (VCYT) Q4 2025 Earnings Call Transcript
Investors are keenly awaiting the transcript of Veracyte Inc.'s (VCYT) Q4 2025 earnings call, scheduled for February 25, 2026. While the announcement of such an event is standard for publicly traded companies, the current unavailability of the actual transcript content prevents any in-depth analysis of the financial data, future outlook, or strategic decisions discussed. The eventual release of these details will be crucial for understanding the company's performance and projections, potentially influencing market sentiment and investment decisions. Without this information, the market remains in a holding pattern, awaiting further clarity.
via Markets Gazette